Nervalin CR Tablet 82.5 mg contains Pregabalin in a controlled-release (CR) formulation designed to provide sustained and consistent drug delivery over 24 hours. This extended-release profile helps maintain stable plasma concentrations, improves tolerability, and allows convenient once-daily dosing. Nervalin CR is primarily indicated for the management of neuropathic pain and certain neurological conditions where long-term pain control and steady symptom relief are essential.

Therapeutic Class

Supplemental anti-epileptic medication

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Nervalin CR Tablet 82.5 mg is indicated for the treatment of:

• Neuropathic pain associated with diabetic peripheral neuropathy (DPN)

• Post-herpetic neuralgia (PHN) following shingles

• Neuropathic pain associated with spinal cord injury

• Fibromyalgia

• Adjunctive therapy for partial-onset seizures

The controlled-release formulation is particularly beneficial for patients who require continuous pain control with improved adherence.

Pharmacology

Pregabalin is a structural analogue of gamma-aminobutyric acid (GABA) but does not directly bind to GABAA, GABAB, or benzodiazepine receptors. Instead, it selectively binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This action reduces calcium influx into presynaptic neurons, leading to decreased release of excitatory neurotransmitters such as glutamate, substance P, and norepinephrine. As a result, abnormal neuronal excitability associated with neuropathic pain and seizures is reduced. Pregabalin exhibits high oral bioavailability and is eliminated largely unchanged through renal excretion.

Dosage and Administration

Nervalin CR Tablet 82.5 mg is intended for once-daily oral administration, preferably taken after the evening meal.

• It may be used as an initial or conversion dose when switching from immediate-release pregabalin formulations.

• Dosage should be individualized based on the indication, patient response, and renal function.

• Tablets must be swallowed whole and should not be crushed, split, or chewed, as this may affect the controlled-release mechanism.

Dose titration should be gradual to minimize adverse effects, and dose adjustments are required in patients with renal impairment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

Nervalin CR Tablet 82.5 mg is contraindicated in patients with known hypersensitivity to pregabalin or any of the tablet excipients.

Side Effects

The most commonly reported adverse effects include dizziness, somnolence, dry mouth, blurred vision, peripheral edema, weight gain, and difficulty with concentration or attention. These effects are usually mild to moderate and may decrease with continued therapy.

Precautions and Warnings

Caution is advised in patients with renal dysfunction, heart failure, or those receiving concomitant central nervous system depressants. Pregabalin may cause dizziness or drowsiness; therefore, patients should avoid driving or operating heavy machinery until they know how the medication affects them. Abrupt discontinuation should be avoided, as it may increase the risk of withdrawal symptoms or seizure exacerbation. Gradual dose tapering is recommended.

Pregnancy and Lactation

Nervalin CR Tablet 82.5 mg should be used during pregnancy only if the potential benefit justifies the possible risk to the fetus. Pregabalin is excreted into breast milk; therefore, caution is advised when administered to breastfeeding mothers.

Storage Conditions

Store in a cool, dry place below 30°C, protected from light and moisture. Keep out of reach of children.